Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $97.6 million.

  • Taysha Gene Therapies' Total Liabilities rose 672.17% to $97.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.6 million, marking a year-over-year increase of 672.17%. This contributed to the annual value of $88.8 million for FY2024, which is 915.7% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Total Liabilities of $97.6 million as of Q3 2025, which was up 672.17% from $84.6 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Total Liabilities registered a high of $244.9 million during Q3 2023, and its lowest value of $83.3 million during Q1 2025.
  • Its 4-year average for Total Liabilities is $111.0 million, with a median of $99.1 million in 2024.
  • As far as peak fluctuations go, Taysha Gene Therapies' Total Liabilities skyrocketed by 14404.84% in 2023, and later crashed by 6266.79% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Total Liabilities (Quarter) stood at $125.3 million in 2022, then decreased by 21.97% to $97.8 million in 2023, then dropped by 9.16% to $88.8 million in 2024, then rose by 9.82% to $97.6 million in 2025.
  • Its last three reported values are $97.6 million in Q3 2025, $84.6 million for Q2 2025, and $83.3 million during Q1 2025.